[1]
Joffe S. Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines. JAMA. 2021 Jan 19:325(3):221-222. doi: 10.1001/jama.2020.25127. Epub
[PubMed PMID: 33315069]
[2]
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021 Feb 4:384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30
[PubMed PMID: 33378609]
[3]
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine. 2020 Dec 31:383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10
[PubMed PMID: 33301246]
[4]
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Medical Research. 2020 Mar 13:7(1):11. doi: 10.1186/s40779-020-00240-0. Epub 2020 Mar 13
[PubMed PMID: 32169119]
[5]
Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta bio-medica : Atenei Parmensis. 2020 Mar 19:91(1):157-160. doi: 10.23750/abm.v91i1.9397. Epub 2020 Mar 19
[PubMed PMID: 32191675]
[6]
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. 2023 Jan:():
[PubMed PMID: 32150360]
[7]
Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cellular and molecular life sciences : CMLS. 2004 Nov:61(21):2738-43
[PubMed PMID: 15549175]
[8]
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature reviews. Cardiology. 2020 May:17(5):259-260. doi: 10.1038/s41569-020-0360-5. Epub
[PubMed PMID: 32139904]
[9]
Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S, Xin Y, Zhuang L. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020 Nov:131():110678. doi: 10.1016/j.biopha.2020.110678. Epub 2020 Aug 24
[PubMed PMID: 32861070]
[10]
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M. Comorbidity and its Impact on Patients with COVID-19. SN comprehensive clinical medicine. 2020:2(8):1069-1076. doi: 10.1007/s42399-020-00363-4. Epub 2020 Jun 25
[PubMed PMID: 32838147]
[11]
Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, Dorscheid DR, Sin DD. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. The European respiratory journal. 2020 May:55(5):. doi: 10.1183/13993003.00688-2020. Epub 2020 May 14
[PubMed PMID: 32269089]
[12]
Padda I, Khehra N, Jaferi U, Parmar MS. The Neurological Complexities and Prognosis of COVID-19. SN comprehensive clinical medicine. 2020:2(11):2025-2036. doi: 10.1007/s42399-020-00527-2. Epub 2020 Sep 29
[PubMed PMID: 33015552]
[13]
Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: Possible mechanisms. Life sciences. 2020 Jul 15:253():117723. doi: 10.1016/j.lfs.2020.117723. Epub 2020 Apr 28
[PubMed PMID: 32360126]
[14]
Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, Huang H, Yang B, Huang C. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. European heart journal. 2020 Jun 7:41(22):2070-2079. doi: 10.1093/eurheartj/ehaa408. Epub
[PubMed PMID: 32391877]
Level 2 (mid-level) evidence
[15]
Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, Ma Z, Huang Y, Liu W, Yao Y, Zeng R, Xu G. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. Journal of the American Society of Nephrology : JASN. 2020 Jun:31(6):1157-1165. doi: 10.1681/ASN.2020030276. Epub 2020 Apr 28
[PubMed PMID: 32345702]
[16]
Raza A, Estepa A, Chan V, Jafar MS. Acute Renal Failure in Critically Ill COVID-19 Patients With a Focus on the Role of Renal Replacement Therapy: A Review of What We Know So Far. Cureus. 2020 Jun 3:12(6):e8429. doi: 10.7759/cureus.8429. Epub 2020 Jun 3
[PubMed PMID: 32642345]
[17]
Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and Liver Manifestations of COVID-19. Journal of clinical and experimental hepatology. 2020 May-Jun:10(3):263-265. doi: 10.1016/j.jceh.2020.03.001. Epub 2020 Apr 1
[PubMed PMID: 32405183]
[18]
Kopel J, Perisetti A, Gajendran M, Boregowda U, Goyal H. Clinical Insights into the Gastrointestinal Manifestations of COVID-19. Digestive diseases and sciences. 2020 Jul:65(7):1932-1939. doi: 10.1007/s10620-020-06362-8. Epub 2020 May 23
[PubMed PMID: 32447742]
[19]
Tanne JH. Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine. BMJ (Clinical research ed.). 2020 Dec 11:371():m4799. doi: 10.1136/bmj.m4799. Epub 2020 Dec 11
[PubMed PMID: 33310748]
[20]
Tanne JH. Covid-19: Pfizer-BioNTech vaccine is rolled out in US. BMJ (Clinical research ed.). 2020 Dec 14:371():m4836. doi: 10.1136/bmj.m4836. Epub 2020 Dec 14
[PubMed PMID: 33318040]
[21]
Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, DeSilva MB, Natarajan K, Bozio CH, Lewis N, Dascomb K, Dixon BE, Birch RJ, Irving SA, Rao S, Kharbanda E, Han J, Reynolds S, Goddard K, Grisel N, Fadel WF, Levy ME, Ferdinands J, Fireman B, Arndorfer J, Valvi NR, Rowley EA, Patel P, Zerbo O, Griggs EP, Porter RM, Demarco M, Blanton L, Steffens A, Zhuang Y, Olson N, Barron M, Shifflett P, Schrag SJ, Verani JR, Fry A, Gaglani M, Azziz-Baumgartner E, Klein NP. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. The New England journal of medicine. 2021 Oct 7:385(15):1355-1371. doi: 10.1056/NEJMoa2110362. Epub 2021 Sep 8
[PubMed PMID: 34496194]
[22]
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet (London, England). 2021 May 15:397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5
[PubMed PMID: 33964222]
Level 2 (mid-level) evidence
[23]
Ioannou GN, Locke ER, O'Hare AM, Bohnert ASB, Boyko EJ, Hynes DM, Berry K. COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study. Annals of internal medicine. 2022 Mar:175(3):352-361. doi: 10.7326/M21-3256. Epub 2021 Dec 21
[PubMed PMID: 34928700]
[24]
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus research. 2020 Oct 15:288():198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13
[PubMed PMID: 32800805]
[25]
Ura T, Yamashita A, Mizuki N, Okuda K, Shimada M. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2021 Jan 8:39(2):197-201. doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24
[PubMed PMID: 33279318]
[26]
Chien KR, Zangi L, Lui KO. Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine. Cold Spring Harbor perspectives in medicine. 2014 Oct 9:5(1):a014035. doi: 10.1101/cshperspect.a014035. Epub 2014 Oct 9
[PubMed PMID: 25301935]
Level 3 (low-level) evidence
[27]
Heaton PM. The Covid-19 Vaccine-Development Multiverse. The New England journal of medicine. 2020 Nov 12:383(20):1986-1988. doi: 10.1056/NEJMe2025111. Epub 2020 Jul 14
[PubMed PMID: 32663910]
[28]
Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infection and drug resistance. 2021:14():3459-3476. doi: 10.2147/IDR.S315727. Epub 2021 Aug 31
[PubMed PMID: 34511939]
Level 3 (low-level) evidence
[29]
Twentyman E, Wallace M, Roper LE, Anderson TC, Rubis AB, Fleming-Dutra KE, Hall E, Hsu J, Rosenblum HG, Godfrey M, Archer WR, Moulia DL, Daniel L, Brooks O, Talbot HK, Lee GM, Bell BP, Daley M, Meyer S, Oliver SE. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022. MMWR. Morbidity and mortality weekly report. 2022 Aug 5:71(31):988-992. doi: 10.15585/mmwr.mm7131a2. Epub 2022 Aug 5
[PubMed PMID: 35925807]
[30]
Goyal L, Zapata M, Ajmera K, Chaurasia P, Pandit R, Pandit T. A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants. Cureus. 2022 Oct:14(10):e29837. doi: 10.7759/cureus.29837. Epub 2022 Oct 2
[PubMed PMID: 36204257]
[31]
Choi KR. A Nursing Researcher's Experience in a COVID-19 Vaccine Trial. JAMA internal medicine. 2021 Feb 1:181(2):157-158. doi: 10.1001/jamainternmed.2020.7087. Epub
[PubMed PMID: 33284328]
[32]
Cabanillas B, Akdis CA, Novak N. Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol? Allergy. 2021 Jun:76(6):1617-1618. doi: 10.1111/all.14711. Epub
[PubMed PMID: 33320974]
[33]
Mahase E. Covid-19: People with history of significant allergic reactions should not receive Pfizer vaccine, says regulator. BMJ (Clinical research ed.). 2020 Dec 10:371():m4780. doi: 10.1136/bmj.m4780. Epub 2020 Dec 10
[PubMed PMID: 33303484]